Literature DB >> 15331286

Hypertrophic cardiomyopathy in childhood.

Barry J Maron1.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a heterogeneous and relatively common genetic cardiac disease that has been the subject of intense scrutiny and investigation for over 40 years. HCM is an important cause of disability and death in patients of all ages, although unexpected sudden death in the young is perhaps the most devastating component of the natural history. Therefore, while HCM is uncommon in pediatric cardiology practice, it is nevertheless a disease of great importance to young people and those clinicians charged with their care. Due to marked heterogeneity in clinical expression, natural history and prognosis, diagnostic and management strategies often represent a dilemma (and even the source of controversy) to both primary care clinicians and cardiovascular specialists. Consequently, it is timely to place perspective and clarify many of these relevant clinical issues, and profile the rapidly evolving concepts regarding HCM, especially as they may impact on this disease in childhood.

Entities:  

Mesh:

Year:  2004        PMID: 15331286     DOI: 10.1016/j.pcl.2004.04.017

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  14 in total

Review 1.  Primary prevention of sudden cardiac death of the young athlete: the controversy about the screening electrocardiogram and its innovative artificial intelligence solution.

Authors:  Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2012-02-12       Impact factor: 1.655

2.  Family Relationships Associated With Communication and Testing for Inherited Cardiac Conditions.

Authors:  Lisa L Shah; Sandra Daack-Hirsch; Anne L Ersig; Anthony Paik; Ferhaan Ahmad; Janet Williams
Journal:  West J Nurs Res       Date:  2018-12-12       Impact factor: 1.967

3.  Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood.

Authors:  M Emmel; N Sreeram; J V deGiovanni; K Brockmeier
Journal:  Z Kardiol       Date:  2005-10

4.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 5.  Importance of genetic evaluation and testing in pediatric cardiomyopathy.

Authors:  Muhammad Tariq; Stephanie M Ware
Journal:  World J Cardiol       Date:  2014-11-26

6.  Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in children.

Authors:  M Emmel; N Sreeram
Journal:  Neth Heart J       Date:  2005-12       Impact factor: 2.380

7.  Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective.

Authors:  Edward K Rhee; John J Nigro; Stephen G Pophal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

8.  RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy.

Authors:  Beth D Kaufman; Scott Auerbach; Sushma Reddy; Cedric Manlhiot; Liyong Deng; Ashwin Prakash; Beth F Printz; Dorota Gruber; Dimitrios P Papavassiliou; Daphne T Hsu; Amy J Sehnert; Wendy K Chung; Seema Mital
Journal:  Hum Genet       Date:  2007-09-13       Impact factor: 4.132

9.  Shared genetic causes of cardiac hypertrophy in children and adults.

Authors:  Hiroyuki Morita; Heidi L Rehm; Andres Menesses; Barbara McDonough; Amy E Roberts; Raju Kucherlapati; Jeffrey A Towbin; J G Seidman; Christine E Seidman
Journal:  N Engl J Med       Date:  2008-04-09       Impact factor: 91.245

10.  Cardiomyopathies in children.

Authors:  Young Mi Hong
Journal:  Korean J Pediatr       Date:  2013-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.